Expression of CAV1 in Tumor Tissues and Its Effect on Survival Prognosis of Patients
-
摘要:
目的 通过生物信息学分析小凹蛋白-1（CAV1）在多种肿瘤中的表达与预后意义及其免疫浸润的相关性，阐明其对肿瘤预后的评估价值。 方法 基于TCGA和GTEx数据库分析CAV1基因在不同肿瘤组织中的mRNA表达水平，通过CPTAC数据库分析CAV1基因在不同肿瘤组织中的蛋白表达水平，单因素COX回归分析CAV1表达与肿瘤患者生存预后之间的相关性，HPA数据库分析CAV1表达的肿瘤免疫组化水平，Spearman相关性分析肿瘤与免疫浸润细胞的相关性。采用多因素COX回归和Nomogram列线图建立BLCA、LGG和HNSC预测评分模型。 结果 CAV1基因在26种肿瘤组织中mRNA异常表达（P < 0.05），CAV1的高表达对膀胱尿路上皮癌（BLCA）、脑低级别胶质癌（LGG）和头颈鳞状细胞癌（HNSC）3种肿瘤患者总生存期产生不良影响，并且在BLCA、LGG和HNSC中与多种肿瘤免疫浸润细胞密切相关。单因素COX回归分析显示CAV1（HR = 1.489，P = 0.0078）和年龄（HR = 1.424，P = 0.0022）是BLCA患者总生存期的危险因素，CAV1（HR = 2.432，P = 0.0006）与WHO grade（HR = 3.023，P = 0.0004）是LGG患者总生存期的危险因素，CAV1（HR = 1.432，P = 0.0085）与临床病理分型（HR = 1.806，P = 0.0006）是HNSC患者总生存期的危险因素。 结论 CAV1基因的表达及调节与BLCA、LGG和HNSC的发生发展、患者的预后、肿瘤免疫有一定的相关性，可能成为改善BLCA、LGG与HNSC患者预后的潜在标志。 Abstract:Objective Bioinformatics was used to analyze the correlation between CAV1 expression and its prognostic value and immune infiltration in various tumors and to clarify its value in evaluating tumor prognosis. Methods The mRNA expression level of CAV1 gene was analyzed based on TCGA and GTEx databases, the protein expression level of CAV1 gene was analyzed by CPTAC database, the correlation between CAV1 expression and survival and prognosis of tumor patients was analyzed by univariate COX regression, and the tumor immunohistochemistry level of CAV1 expression was analyzed by HPA database. Spearman correlation analysis of tumor and immune infiltrating cells. Results The mRNA expression of the CAV1 gene was different in 26 tumor tissues（P < 0.05）, and the high expression of CAV1 had adverse effects on the overall survival of bladder urothelial carcinoma, low-grade glial carcinoma of the brain and head and neck squamous cell carcinoma. It is closely related to various tumor immune infiltrating cells in BLCA, LGG, and HNSC. Univariate COX regression analysis showed that CAV1（HR = 1.489, P = 0.0078） and age（HR = 1.424, P = 0.0022） were risk factors for overall survival in BLCA patients, while CAV1（HR = 2.432, P = 0.0006） and WHO grade（HR = 3.023, P = 0.0004） were risk factors for overall survival in LGG patients.CAV1（HR = 1.432, P = 0.0085） and clinicopathological classification（HR = 1.806, P = 0.0006） were risk factors for overall survival in HNSC patients. Conclusion The expression and regulation of CAV1 gene are correlated with the occurrence and development of BLCA, LGG and HNSC, patient prognosis and tumor immunity. They may be a prognostic factor of BLCA, LGG and HNSC patients. -
Key words:
- CAV1 /
- Human tumor /
- Survival Prognosis /
- Immunity
-
图 1 CAV1基因在人类肿瘤组织和正常组织中的mRNA表达分析
*P < 0.05；**P < 0.01；***P < 0.001。
Figure 1. mRNA expression analysis of CAV1 gene in human tumor tissues and normal tissues
图 2 CAV1基因在不同癌症组织和正常组织中的总蛋白表达分析
Figure 2. Total protein expression analysis of CAV1 gene in different cancer tissues and normal tissues
图 3 CAV1基因在BLCA、LGG与HNSC肿瘤组织中的预后KM曲线图
A：CAV1与BLCA患者生存预后相关性；B：CAV1与LGG患者生存预后相关性；C：CAV1与HNSC患者生存预后相关性。
Figure 3. Prognostic KM curve of CAV1 gene in BLCA，LGG and HNSC tumors
图 4 BLCA、LGG和HNSC肿瘤组织和正常组织的免疫组化图 （×100）
A：膀胱组织与膀胱肿瘤组织CAV1表达；B：脑组织与脑低级别胶质肿瘤组织CAV1表达；C：头颈部与头颈鳞状细胞肿瘤组织CAV1表达。
Figure 4. Immunohistochemical maps of BLCA，LGG and HNSC tumor tissue and normal tissue （×100）
图 5 CAV1基因在3种不同肿瘤组织中与免疫浸润细胞相关性棒棒糖图
A：CAV1在LGG中与免疫浸润细胞相关性；B：CAV1在HNSC中与免疫浸润细胞相关性；C：CAV1在BLCA中与免疫浸润细胞相关性。*P < 0.05，**P < 0.01，***P < 0.001。
Figure 5. Lollipop map of CAV1 gene correlation with immunoinfiltrating cells in three different tumor tissues
图 6 CAV1表达对BLCA总生存期的影响因素COX回归分析及其Nomogram模型的构建与评估
A：单、多因素COX回归分析；B：Nomogram模型；C：校准曲线。
Figure 6. COX regression analysis of influencing factors of CAV1 expression on overall survival of BLCA and Nomogram model construction and evaluation
图 7 CAV1表达对LGG总生存期的影响因素COX回归分析及其Nomogram模型的构建与评估
A：单、多因素COX回归分析；B：Nomogram模型；C：校准曲线。
Figure 7. 7Cox regression analysis of factors influencing CAV1 expression on overall survival of LGG and Nomogram model construction and evaluation
-
[1] Roy P S,Saikia B J. Cancer and cure: A critical analysis[J]. Indian J Cancer,2016,53(3):441-442. doi: 10.4103/0019-509X.200658 [2] Yahya E B,Alqadhi A M. Recent trends in cancer therapy: A review on the current state of gene delivery[J]. Life Sci,2021,15(269):119087. [3] 曹毛毛,陈万青. GLOBOCAN 2020全球癌症统计数据解读[J]. 中国医学前沿杂志,2021,13(3):63-69. [4] 马丽萍,丁春燕,田梅,等. 信号转导和转录激活因子3及小凹蛋白1在X射线诱导肺腺癌A549细胞早衰中的调控关系研究[J]. 中国医学装备,2021,18(3):1-5. [5] 黄青云. LncRNA HOTAIR通过MiR-203/Caveolin-1对乳腺癌细胞增殖、迁移和侵袭的影响[D]. 南昌: 南昌大学, 2021. [6] 李倩. Caveolin1通过OCTN2（SLC22A5）逆转结直肠癌耐药性[D]. 厦门: 厦门大学, 2021. [7] 高冬梅,张小芳,安杰,等. Cav-1对EGFR敏感基因突变非小细胞肺癌患者厄洛替尼治疗耐药的机制研究[J]. 解放军医药杂志,2022,34(3):1-5. [8] 邓心怡,高子煦,王璐,等. 环指蛋白157通过下调小凹蛋白-1表达参与ERK通路激活促进黑素瘤细胞增殖[J]. 中国临床医学,2023,30(2):257-264. [9] 崔玉洁,杜梦颖,李硕,等. Caveolin-1调控VEGFR-2对肺癌细胞增殖及侵袭的影响[J]. 现代中西医结合杂志,2022,31(20):2798-2802. [10] 韩蕴,李洪艳,张叶军,等. Caveolin-1和ER-α36相互作用促进胶质瘤细胞生长[J]. 癌症,2022,41(3):142-151. [11] Wang Y,Song Y,Che X,et al. Caveolin-1 enhances RANKL-induced gastric cancer cell migration[J]. Oncol Rep,2018,40(3):1287-1296. [12] 邵伟伟,王树人,刘水,等. 小窝蛋白1和表皮生长因子受体在肺腺癌的表达及临床意义[J]. 江苏医药,2023,49(2):158-163. [13] 谭超,邹黎黎. 小凹蛋白1与肿瘤的研究进展[J]. 中华肿瘤防治杂志,2015,22(6):483-488. [14] Sung H,Ferlay J,Siegel R L,et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries[J]. CA Cancer J Clin,2021,71(3):209-249. doi: 10.3322/caac.21660 [15] Vivian J,Rao A A,Nothaft F A,et al. Toil enables reproducible,open source,big biomedical data analyses[J]. Nature Biotechnology,2017,35(4):314-316. doi: 10.1038/nbt.3772 [16] Chen F,Chandrashekar D S,Varambally S,et al. Pan-cancer molecular subtypes revealed by mass-spectrometry-based proteomic characterization of more than 500 human cancers[J]. Nat Commun,2019,10(1):5679. doi: 10.1038/s41467-019-13528-0 [17] Bindea G,Mlecnik B,Tosolini M,et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer[J]. Immunity,2013,39(4):782-795. doi: 10.1016/j.immuni.2013.10.003 [18] 王红磊,李昕宇,蒙椿海,等. Caveolin-1在肿瘤中的作用机制研究概况[J]. 广西中医药大学学报,2021,24(1):54-57. [19] 贾帅楠,李劲涛,赵丽娇,等. 环境致癌物与病毒协同致癌作用的研究进展[J]. 病毒学报,2018,34(4):601-609. [20] 余水红,李帆,金耀,等. 基于数据库探索GPX4基因在泛癌中的潜在价值[J]. 济宁医学院学报,2022,45(4):278-282. [21] 周威. TAF1L基因异常表达对口腔鳞状细胞癌病变作用的研究[D]. 深圳: 深圳大学, 2019. [22] 吴秀珍. 高通量基因测序在胃肠道恶性肿瘤中的临床意义[D]. 苏州: 苏州大学, 2017. [23] 彭贻龙,郑彩云. 骨肉瘤中FoxM1、Sox9基因异常表达与肿瘤病理特征的相关性研究[J]. 海南医学院学报,2018,24(7):797-799. [24] 谭金晶. DLK1基因异常表达及其促进肺癌细胞侵袭的分子机制[D]. 北京: 北京协和医学院, 2014. [25] Quest A F,Lobos-González L,Nuñez S,et al. The caveolin-1 connection to cell death and survival[J]. Curr Mol Med,2013,13(2):266-281. doi: 10.2174/156652413804810745 [26] Lin X,Chai G,Wu Y,et al. A methylation regulates the epithelial mesenchymal transition of cancer cells and translation of Snail[J]. Nat Commun,2019,10(1):2065. doi: 10.1038/s41467-019-09865-9 [27] 陈胜武,赵恒伍,高轶轩. Toll样受体2在泛癌中的表达、对预后的影响及其作用机制[J]. 中国医科大学学报,2022,51(9):810-816. -
下载:
点击查看大图
计量
- 文章访问数: 1360
- HTML全文浏览量: 1329
- PDF下载量: 21
- 被引次数: 0
